|
|
| Article |
Notes |
|
Favorable Prognosis |
|
Core Binding Factor (CBF) AML -
t(8;21)(q22;q22), inv(16)(p13;q22), t(16;16)(p13;q22) |
|
Pretreatment cytogenetic
abnormalities are predictive of induction success,
cumulative incidence of relapse, and overall
survival in adult patients with de novo acute
myeloid leukemia: results from Cancer and Leukemia
Group B (CALGB 8461) |
t(8;21)(q22;q22), inv(16)(p13;q22),
t(16;16)(p13;q22), t(9;11) |
|
The importance of diagnostic
cytogenetics on outcome in AML: analysis of 1,612
patients entered into the MRC AML 10 trial. The
Medical Research Council Adult and Children's
Leukaemia Working Parties. |
t(8;21), t(15;17) or inv(16) |
|
Individual patient data-based
meta-analysis of patients aged 16 to 60 years with core
binding factor acute myeloid leukemia: a survey of the
German Acute Myeloid Leukemia Intergroup. |
t(8;21)(q22;q22), inv(16) |
|
Acute promyelocytic leukemia t(15;17)(q22;q12-21) |
|
The importance of diagnostic
cytogenetics on outcome in AML: analysis of 1,612
patients entered into the MRC AML 10 trial. The
Medical Research Council Adult and Children's
Leukaemia Working Parties. |
t(8;21), t(15;17) or inv(16) |
|
Unfavorable Prognosis |
|
Incidence and prognosis of c-KIT and
FLT3 mutations in core binding factor (CBF) acute
myeloid leukaemias. |
t(8;21), FLT3, cKIT exon 8 mutations |
|
KIT-D816 mutations in
AML1-ETO-positive AML are associated with impaired
event-free and overall survival. |
t(8;21)/AML1-ETO, KIT-D816V, FLT3 and NRAS mutations |
|
Prognostic impact of c-KIT mutations
in core binding factor leukemias: an Italian
retrospective study. |
c-Kit TKD(816), t(8;21) |
|
Incidence and prognostic impact of
c-Kit, FLT3, and Ras gene mutations in core binding
factor acute myeloid leukemia (CBF-AML). |
RTK c-Kit, FLT3 and Ras mutations |
|
Tyrosine kinase mutations of JAK2 are rare events in AML but influence
prognosis of patients with CBF-leukemias. |
JAK2 V617F mutation |
|
